Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...
A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.
The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...
A popular diabetes drug just got a major new approval—and it could be a game-changer for millions of Americans at risk for ...
Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...
The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...
Medpage Today on MSN6d
Faricimab Again Linked to Rare but Severe Eye Adverse EffectsAt a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...
As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, ...
Luo, Y.N., Lu, J., Liang, G.H. and Ma, W.H. (2025) Long-Term Opacity of Intraocular Lens after Cataract Surgery in 1 Case. Journal of Biosciences and Medicines, 13, 206-214. doi: ...
"OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related ... dose-escalation study to assess drug safety via intravitreal injection in three ...
The introduction of the first-generation anti-VEGF drugs—Macugen (pegaptanib), Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab)—has since been followed by longer-lasting agents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback